This round of financing will support the preclinical development and early clinical validation of two leading programs, discovery of future pipelines, expansion of the leadership team, and continued investments in the company's core technology platforms.

Epigenic's EPIREG™ technology offers a compelling alternative to the traditional cleavage-dependent gene editing tools by which altering the DNA sequence would raise safety concerns. By precisely modulating gene expression(s) at epigenetic levels, EPIREG™ is expected to achieve potent and durable silencing of target gene(s) to provide revolutionary and novel solutions to patients with chronic diseases.

"In two years since the inception, Epigenic has made significant progress towards transforming cutting-edge science into life-saving epigenome medicines. Now we have developed targeted therapeutic strategies." said Bob Zhang, co-founder and CEO of Epigenic Therapeutics. "We are honored and grateful to have the support from top-tier global investors as we continue our mission to pioneer innovations in epigenome medicines to be ultimately implemented in patient care."

"Gene therapy is one of the most exciting areas of biotechnology in recent years." said Dr. Kan Chen, Partner of Qiming Venture Partners. "Qiming has been closely following the latest technology development and breakthroughs, and how they can be applied to meet unmet medical needs of more patients. Epigenic Therapeutics leverages globally leading epigenetic modulation technology to develop innovative therapies for various chronic diseases. With a passionate and experienced team, the company has been steadily and efficiently moving forward with the development of technology platforms and pipelines. We look forward to Epigenic Therapeutics bringing hope and treatments to global patients soon."

"Epigenetic modulations have shown remarkably superior efficiency, durability, as well as safety profile compared to other genetic tools. Epigenetic Therapeutics is a leader in this space and has leveraged the unique advantage of the platform to produce potentially best-in-disease product profile." said Steven Wang, Partner of OrbiMed Asia Partners. "We are impressed with the preclinical data and the execution capability of the Epigenic Therapeutics leadership team. We look forward to supporting the company to bring the two development candidates to clinic."